Tudor Investment Corp ET AL increased its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 279.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 82,386 shares of the biopharmaceutical company’s stock after acquiring an additional 60,685 shares during the quarter. Tudor Investment Corp ET AL’s holdings in Bristol-Myers Squibb were worth $4,591,000 as of its most recent filing with the SEC.
A number of other large investors have also added to or reduced their stakes in the stock. Tradewinds Capital Management LLC lifted its position in shares of Bristol-Myers Squibb by 34.6% during the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 500 shares during the period. American National Bank increased its stake in Bristol-Myers Squibb by 11.7% during the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 225 shares in the last quarter. Blue Chip Partners Inc. increased its stake in Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 15 shares in the last quarter. BDO Wealth Advisors LLC bought a new stake in Bristol-Myers Squibb during the 2nd quarter valued at $123,000. Finally, Acrospire Investment Management LLC increased its stake in Bristol-Myers Squibb by 633.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,200 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 1,900 shares in the last quarter. 69.66% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have recently issued reports on the stock. UBS Group reiterated a “buy” rating and issued a $72.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Vetr upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 target price for the company in a research note on Monday, October 9th. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. BMO Capital Markets reissued a “sell” rating and issued a $49.00 price target on shares of Bristol-Myers Squibb in a report on Monday, September 4th. Finally, Citigroup increased their price target on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a report on Wednesday, October 18th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $64.42.
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the transaction, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Theodore R. Samuels II acquired 4,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were bought at an average price of $62.30 per share, with a total value of $249,200.00. Following the completion of the purchase, the director now directly owns 22,000 shares in the company, valued at $1,370,600. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Co (BMY) traded up $0.03 during trading on Tuesday, hitting $61.31. The company’s stock had a trading volume of 6,472,501 shares, compared to its average volume of 4,930,000. Bristol-Myers Squibb Co has a 1-year low of $46.01 and a 1-year high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. The company has a market cap of $100,350.00, a P/E ratio of 24.14, a P/E/G ratio of 2.32 and a beta of 1.17.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.77 earnings per share. equities research analysts forecast that Bristol-Myers Squibb Co will post 2.99 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 annualized dividend and a dividend yield of 2.61%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is currently 61.42%.
COPYRIGHT VIOLATION NOTICE: This report was first published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.truebluetribune.com/2018/01/03/tudor-investment-corp-et-al-buys-60685-shares-of-bristol-myers-squibb-company-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.